References
- Roeder I, Horn M, Glauche I, Hochhaus A, Mueller M C, Hoeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12: 1181–1184
- Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878
- Quintás-Cardama A, Kantarjian H, Jones D, Talpaz M, Jabbow E, O'Brien S, et al. Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. J Clin Oncol 2006; 24(18S), Abstract no. 6525
- Rousselot P, Huguet F, Rea D, Legros L, Cayuela J M, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60
- Michor F, Hughes T P, Iwasa Y, Branford S, Shah N P, Sawyers C L, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267–1270
- Krause D S, Lazarides K, von Andrian U H, Van Etten R A. Requirement for CD44 in homing and engraftment of BCR – ABL-expressing leukemic stem cells. Nat Med 2006; 12: 1175–1180